WO2015017423A3 - Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture - Google Patents
Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture Download PDFInfo
- Publication number
- WO2015017423A3 WO2015017423A3 PCT/US2014/048645 US2014048645W WO2015017423A3 WO 2015017423 A3 WO2015017423 A3 WO 2015017423A3 US 2014048645 W US2014048645 W US 2014048645W WO 2015017423 A3 WO2015017423 A3 WO 2015017423A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modified release
- manufacture
- methods
- acid derivative
- folic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016531822A JP2016525576A (en) | 2013-07-29 | 2014-07-29 | Stabilized modified release folic acid derivative composition, therapeutic use thereof and production method thereof |
EP14832791.9A EP3027178A2 (en) | 2013-07-29 | 2014-07-29 | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
CA2919213A CA2919213A1 (en) | 2013-07-29 | 2014-07-29 | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361859627P | 2013-07-29 | 2013-07-29 | |
US61/859,627 | 2013-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015017423A2 WO2015017423A2 (en) | 2015-02-05 |
WO2015017423A3 true WO2015017423A3 (en) | 2015-04-02 |
Family
ID=52390702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/048645 WO2015017423A2 (en) | 2013-07-29 | 2014-07-29 | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150030676A1 (en) |
EP (1) | EP3027178A2 (en) |
JP (1) | JP2016525576A (en) |
CA (1) | CA2919213A1 (en) |
WO (1) | WO2015017423A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016185413A1 (en) | 2015-05-20 | 2016-11-24 | Nestec S.A. | Modified release formulations |
WO2016185412A1 (en) * | 2015-05-20 | 2016-11-24 | Nestec S.A. | Immediate release formulations |
EP3355865A1 (en) | 2015-09-29 | 2018-08-08 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
WO2023084460A1 (en) * | 2021-11-11 | 2023-05-19 | Ln Laboratories Pvt Ltd | Oral dispersible film comprising l-methylfolate and process thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080038343A1 (en) * | 2006-07-06 | 2008-02-14 | Kristina King | Pharmaceutical composition containing a tetrahydrofolic acid |
US20080268045A1 (en) * | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
WO2012030927A2 (en) * | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
US20120128771A1 (en) * | 2005-05-02 | 2012-05-24 | Venkatesh Gopi M | Timed, pulsatile release systems |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH693905A5 (en) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stable crystalline salts of 5-methyl tetrahydrofolic acid. |
EP1879586A1 (en) * | 2005-03-10 | 2008-01-23 | Sciele Pharma, Inc. | Nutritional preparations comprising folates and essential fatty acids |
-
2014
- 2014-07-29 JP JP2016531822A patent/JP2016525576A/en active Pending
- 2014-07-29 EP EP14832791.9A patent/EP3027178A2/en not_active Withdrawn
- 2014-07-29 US US14/445,949 patent/US20150030676A1/en not_active Abandoned
- 2014-07-29 CA CA2919213A patent/CA2919213A1/en not_active Abandoned
- 2014-07-29 WO PCT/US2014/048645 patent/WO2015017423A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120128771A1 (en) * | 2005-05-02 | 2012-05-24 | Venkatesh Gopi M | Timed, pulsatile release systems |
US20080038343A1 (en) * | 2006-07-06 | 2008-02-14 | Kristina King | Pharmaceutical composition containing a tetrahydrofolic acid |
US20080268045A1 (en) * | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
WO2012030927A2 (en) * | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
Also Published As
Publication number | Publication date |
---|---|
US20150030676A1 (en) | 2015-01-29 |
EP3027178A2 (en) | 2016-06-08 |
WO2015017423A2 (en) | 2015-02-05 |
CA2919213A1 (en) | 2015-02-05 |
JP2016525576A (en) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123391T1 (en) | (2S)-N-[(1S)-1-CYANO-2-PHYNYLATHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS INHIBITORS OF DIPEPTYLYPEPTIDASE I | |
EA201591371A1 (en) | Pyridine derivatives as easily degraded inhibitors ROCK | |
PH12015501965B1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
PH12015502002A1 (en) | Tripeptide epoxy ketone protease inhibitors | |
EA033544B1 (en) | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors | |
EA201300669A1 (en) | SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION | |
UA114906C2 (en) | Heterocyclyl compounds | |
MX2016010899A (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue. | |
EA201500112A1 (en) | 3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES | |
UA107550C2 (en) | Estra-1,3,5 (10),16-tetraene 3-carboxamide derivatives, methods for their production, pharmaceutical preparations which containing them, and their use for drugs production | |
MX368903B (en) | THERAPEUTIC COMPOUNDS and USES THEREOF. | |
EA032951B1 (en) | Glutarimide derivative, use thereof, pharmaceutical composition based thereon, process for preparing same | |
JO3326B1 (en) | Tripeptide Epoxy Ketone Protease Inhibitors | |
PH12015500823A1 (en) | Modified release formulations for oprozomib | |
MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
MX2015002005A (en) | Combination of pi3k inhibitor and c-met inhibitor. | |
WO2015017423A3 (en) | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
TR201819662T4 (en) | Orally dispersible film composition containing enalapril for the treatment of childhood hypertension. | |
WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
EA201200799A1 (en) | HEPATATROPETECTED MEDICINE | |
TH161822A (en) | Seaboria treatment | |
BR112017003425A2 (en) | pharmaceutical composition for the treatment of acute dental or mandibular pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14832791 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2919213 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016531822 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014832791 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014832791 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14832791 Country of ref document: EP Kind code of ref document: A2 |